Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PHC Holdings Corporation (6523:JPX), powered by AI.
PHC Holdings Corporation is currently trading at ¥1,060. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for PHC Holdings Corporation on Alpha Lenz.
PHC Holdings Corporation's P/E ratio is 12.8.
“PHC Holdings Corporation trades at a P/E of 12.8 (undervalued) with modest ROE of 7.5%.”
Ask for details →PHC Holdings Corporation is a diversified healthcare technology company specializing in the development, manufacture, and sale of healthcare devices and services. Serving patients, healthcare professionals, and researchers in over 125 countries, the company focuses on key areas such as diabetes management, healthcare IT solutions, diagnostics, and life sciences. Its product portfolio encompasses blood glucose monitoring systems, continuous glucose monitoring technology, diagnostic testing equipment, clinical testing reagents, and advanced solutions for cancer pathology and cell preservation. PHC Holdings also delivers healthcare software, including electronic medical record systems and pharmacy management tools, supporting the digital transformation of medical facilities. The company is recognized for integrating precision technology and digital solutions to advance basic research, diagnosis, and medical treatment, playing a vital role in improving healthcare outcomes globally. Headquartered in Tokyo, PHC Holdings leverages decades of expertise to offer innovative products and services that support early detection, disease management, and medical research across a broad spectrum of healthcare needs.
“PHC Holdings Corporation trades at a P/E of 12.8 (undervalued) with modest ROE of 7.5%.”
Ask for details →PHC Holdings Corporation (ticker: 6523) is a company listed on JPX in the Healthcare sector (Medical Devices). It has approximately 9,245 employees. Market cap is $133.7B.
The current price is 1,060 with a P/E ratio of 12.75x and P/B of 0.94x.
ROE is 7.46% and operating margin is 6.35%. Annual revenue is $361.6B.